Andere Kunden interessierten sich auch für
![Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics]( "Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics")
Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics110,99 €![Targeted Therapies in Cancer]( "Targeted Therapies in Cancer")
Targeted Therapies in Cancer81,99 €![Clinical Applications of Nuclear Medicine Targeted Therapy]( "Clinical Applications of Nuclear Medicine Targeted Therapy")
Clinical Applications of Nuclear Medicine Targeted Therapy119,99 €![Molecularly Targeted Therapy for Childhood Cancer]( "Molecularly Targeted Therapy for Childhood Cancer")
Molecularly Targeted Therapy for Childhood Cancer147,99 €![Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity]( "Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity")
Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity132,99 €![PET/CT in Melanoma]( "PET/CT in Melanoma")
PET/CT in Melanoma37,99 €![Melanoma, an Issue of Hematology/Oncology Clinics of North America]( "Melanoma, an Issue of Hematology/Oncology Clinics of North America")
Melanoma, an Issue of Hematology/Oncology Clinics of North America68,99 €
Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas - over-exposure to ultraviolet light - is well known, effective treatment has remained challenging.
The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.
This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.
The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.
This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.
From the reviews:
"This book is a multiauthored edition, with contributors and editors who are experts in their fields regarding new therapeutic approaches for melanoma. ... It is a highly technical volume and is directed toward true melanoma mavins, both clinical and laboratory research based, who continue to work at the translational interface. ... I recommend this to all those clinical, translational, and laboratory investigators committed to moving the field forward in the development of treatment for melanoma." (Janice P. Dutcher, Medical Oncology, Vol. 30, 2013)
"This book is a multiauthored edition, with contributors and editors who are experts in their fields regarding new therapeutic approaches for melanoma. ... It is a highly technical volume and is directed toward true melanoma mavins, both clinical and laboratory research based, who continue to work at the translational interface. ... I recommend this to all those clinical, translational, and laboratory investigators committed to moving the field forward in the development of treatment for melanoma." (Janice P. Dutcher, Medical Oncology, Vol. 30, 2013)